Abstract: The invention provides methods and compositions for using actin for making micro- and nano-scale structures, including masking of two-dimentsional surfaces and non-conductive three dimensional spacers.

Abstract: Tripeptide and tetrapeptide sulfones, pharmaceutical compositions containing them, their pharmaceutical use, and their preparation, are disclosed. The compounds are useful in potentiating the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exerting toxicity in tumor cells, elevating the production of GM progenitors in bone marrow cells, stimulating the differentiation of bone marrow, mitigating the myelosuppressive effects of chemotherapeutic agents, and modulating hematopoiesis in bone marrow.

Abstract: The object of the present invention is to provide a suppressant for neuronal cell death effective for various diseases which inhibits a constitutive active forming of calcineurin and has less side effect. An inhibitor of constitutive active forming of calcineurin, more specifically a drug which inhibits cleavage of calcineurin subunit A (CaNA) by calpain. Examples thereof include peptides having the amino acid sequence of FDGATAAARKEVIRNK (SEQ No. 1) and REESESVLTLKGLTPTG (SEQ No. 2).

Abstract: An object of the invention is to provide an antimicrobial peptide having an amino acid sequence which is different from a peptide existing and functioning as an antimicrobial peptide in the natural world and is not based on the conventional developmental approach for an antimicrobial peptide-containing antimicrobial agent, and a polynucleotide coding for said peptide. Another object is to provide an antimicrobial agent which contains such an antimicrobial peptide. Namely, an antimicrobial peptide represented by a general formula (1) (Xa)n-S??(1) wherein Xa of the formula (1) is a hydrophilic amino acid residue, n is an integer of from 1 to 6, two or more of the Xa may be the same or different from one another, S is a peptide represented by hydrophobic amino acid part-basic amino acid part-bridge part-basic amino acid part-hydrophobic amino acid part, and amino acid residue of the bridge part is selected from the group consisting of hydrophobic amino acids and neutral amino acids.

Abstract: Medical devices with polymer coatings designed to control the release of angiotensin-(1-7) receptor agonists from medical devices are disclosed. The present application also discloses providing vascular stents with angiotensin-(1-7) receptor agonist-containing controlled-release coatings. Methods for treating or inhibiting post-stent implantation restenosis as well as improving vascular endothelial function in patients are also provided.

Abstract: Compounds of formula (SEQ ID NO:2) and (SEQ ID NO:3), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.